Related Experiment Video

Updated: Dec 16, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.0K

A New TGF-β1 Inhibitor, CTI-82, Antagonizes Epithelial-Mesenchymal Transition through Inhibition of Phospho-SMAD2/3

Ji-Hoon Jeong1, Hyunhee Kim1, Seung-Ho Park1

  • 1Department of Biomedical Sciences, Asan Medical Center, AMIST, University of Ulsan College of Medicine, Seoul 05505, Korea.

Biology
|July 2, 2020
PubMed

Insights

A new compound, CTI-82, effectively inhibits transforming growth factor-β1 (TGF-β1)-induced epithelial-mesenchymal transition (EMT). This natural compound suppresses lung cancer cell migration and metastasis, offering a potential new cancer treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Transforming growth factor-β1 (TGF-β1) is upregulated in the tumor microenvironment, promoting cancer progression and metastasis via epithelial-mesenchymal transition (EMT).
  • Inhibition of TGF-β1 signaling is a key therapeutic strategy for various cancers.
  • Developing novel, non-toxic TGF-β1 inhibitors from natural compounds is an active area of research.

Purpose of the Study:

  • To identify and develop a novel TGF-β1 inhibitor capable of suppressing EMT in cancer cells.
  • To evaluate the efficacy of the identified compound, CTI-82, in preclinical models.

Main Methods:

  • In vitro screening and characterization of chalcone-like compounds.
  • Assessment of CTI-82's effect on TGF-β1-induced EMT in A549 lung cancer cells.
  • Analysis of cell migration, metastasis, SMAD2/3 phosphorylation, and EMT marker expression.

Main Results:

  • CTI-82 was identified as an improved chalcone-like compound with TGF-β1 inhibitory activity.
  • CTI-82 effectively blocked TGF-β1-induced EMT, reducing cell migration and metastasis in A549 lung cancer cells.
  • CTI-82 inhibited TGF-β1-induced SMAD2/3 phosphorylation and downregulated key EMT markers.

Conclusions:

  • CTI-82 demonstrates potent inhibition of TGF-β1 signaling and EMT.
  • CTI-82 shows promise as a therapeutic agent to suppress tumor growth, migration, and metastasis.
  • Further investigation into CTI-82 for cancer treatment is warranted.
Keywords:
EMTTGF-β1TGF-β1 inhibitorchalconeinvasionmigration

More Related Videos

Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.3K
Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

11.6K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.2K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.7K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.6K